Total Payments
$3,169
2024 Payments
$694.66
Companies
20
Transactions
165
Medicare Patients
891
Medicare Billing
$917,329
Payment Breakdown by Category
Food & Beverage$2,703 (85.3%)
Other$396.00 (12.5%)
Education$69.99 (2.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,703 | 163 | 85.3% |
| Honoraria | $396.00 | 1 | 12.5% |
| Education | $69.99 | 1 | 2.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Horizon Therapeutics plc | $704.93 | 9 | $0 (2023) |
| Amgen Inc. | $590.21 | 38 | $0 (2024) |
| ABBVIE INC. | $422.10 | 34 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $411.03 | 38 | $0 (2024) |
| Janssen Biotech, Inc. | $239.24 | 6 | $0 (2024) |
| Lilly USA, LLC | $235.67 | 13 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $129.77 | 5 | $0 (2023) |
| GlaxoSmithKline, LLC. | $107.91 | 6 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $60.10 | 3 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $46.98 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $694.66 | 53 | ABBVIE INC. ($201.49) |
| 2023 | $627.69 | 29 | Lilly USA, LLC ($198.26) |
| 2022 | $1,245 | 40 | Horizon Therapeutics plc ($531.86) |
| 2021 | $601.83 | 43 | Horizon Therapeutics plc ($150.23) |
All Payment Transactions
165 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $12.86 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $21.30 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $13.57 | General |
| Category: Inflammation | ||||||
| 12/06/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $10.26 | General |
| Category: Dermatology | ||||||
| 12/05/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $12.51 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological) | Food and Beverage | In-kind items and services | $14.92 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $28.62 | General |
| Category: Not Applicable | ||||||
| 11/12/2024 | Invivyd Inc | PEMGARDA (Biological) | Food and Beverage | In-kind items and services | $16.08 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $15.61 | General |
| Category: IMMUNOLOGY | ||||||
| 11/08/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $9.41 | General |
| Category: IMMUNOLOGY | ||||||
| 11/08/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $9.40 | General |
| Category: Inflammation | ||||||
| 11/05/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $17.67 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/15/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $23.56 | General |
| Category: IMMUNOLOGY | ||||||
| 09/19/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $7.49 | General |
| Category: Dermatology | ||||||
| 09/19/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $6.11 | General |
| Category: Dermatology | ||||||
| 09/18/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $6.86 | General |
| Category: Inflammation/Rare Disease | ||||||
| 09/10/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $31.78 | General |
| Category: IMMUNOLOGY | ||||||
| 09/06/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $10.94 | General |
| Category: Dermatology | ||||||
| 09/03/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $9.13 | General |
| Category: IMMUNOLOGY | ||||||
| 08/27/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $10.01 | General |
| Category: Dermatology | ||||||
| 08/20/2024 | Fresenius Kabi USA, LLC | IDACIO (Biological) | Food and Beverage | In-kind items and services | $25.44 | General |
| Category: Biosimilars | ||||||
| 08/16/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $8.74 | General |
| Category: Dermatology | ||||||
| 08/16/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $0.91 | General |
| Category: Dermatology | ||||||
| 08/15/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $14.95 | General |
| Category: Inflammation/Rare Disease | ||||||
| 08/06/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $9.67 | General |
| Category: Dermatology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 265 | 42,856 | $1.1M | $455,464 |
| 2022 | 9 | 241 | 10,025 | $580,629 | $198,757 |
| 2021 | 11 | 259 | 9,676 | $598,248 | $249,510 |
| 2020 | 5 | 126 | 178 | $44,870 | $13,597 |
Total Patients
891
Total Services
62,735
Medicare Billing
$917,329
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 20 | 6,325 | $474,375 | $202,767 | 42.7% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 14 | 28,080 | $224,640 | $130,844 | 58.2% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 19 | 7,950 | $198,750 | $83,821 | 42.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 68 | 232 | $80,040 | $18,716 | 23.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 44 | 71 | $28,755 | $7,101 | 24.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 41 | 79 | $25,075 | $5,652 | 22.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 31 | 31 | $15,915 | $3,625 | 22.8% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 17 | 46 | $7,450 | $2,169 | 29.1% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 11 | 42 | $5,838 | $768.60 | 13.2% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 20 | 3,375 | $253,125 | $101,439 | 40.1% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2022 | 12 | 6,300 | $221,250 | $74,601 | 33.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 44 | 75 | $30,375 | $7,241 | 23.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 36 | 61 | $21,045 | $5,035 | 23.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 36 | 36 | $18,180 | $4,099 | 22.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 37 | 69 | $17,250 | $2,864 | 16.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 28 | 43 | $12,900 | $2,537 | 19.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 15 | 36 | $5,004 | $685.60 | 13.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 13 | 30 | $1,500 | $255.20 | 17.0% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2021 | 19 | 3,025 | $226,875 | $123,522 | 54.4% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2021 | 14 | 5,450 | $218,000 | $74,645 | 34.2% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2021 | 12 | 860 | $64,500 | $29,387 | 45.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 42 | 57 | $22,010 | $6,147 | 27.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 38 | 38 | $18,490 | $5,189 | 28.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 42 | 87 | $21,750 | $4,114 | 18.9% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 19 | 28 | $9,660 | $2,489 | 25.8% |
About Diane Schmitz, PA-C
Diane Schmitz, PA-C is a Physician Assistant healthcare provider based in Salem, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/08/2018. The National Provider Identifier (NPI) number assigned to this provider is 1497238273.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Diane Schmitz, PA-C has received a total of $3,169 in payments from pharmaceutical and medical device companies, with $694.66 received in 2024. These payments were reported across 165 transactions from 20 companies. The most common payment nature is "Food and Beverage" ($2,703).
As a Medicare-enrolled provider, Schmitz has provided services to 891 Medicare beneficiaries, totaling 62,735 services with total Medicare billing of $917,329. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Physician Assistant
- Location Salem, OR
- Active Since 09/08/2018
- Last Updated 12/06/2019
- Taxonomy Code 363A00000X
- Entity Type Individual
- NPI Number 1497238273
Products in Payments
- KRYSTEXXA (Biological) $798.27
- Enbrel (Biological) $362.86
- RINVOQ (Biological) $343.64
- TALTZ (Drug) $235.67
- COSENTYX (Drug) $210.81
- COSENTYX (Biological) $200.22
- TREMFYA (Drug) $173.70
- SAPHNELO (Biological) $129.77
- BENLYSTA (Biological) $107.91
- SKYRIZI (Biological) $64.39
- STRENSIQ (Biological) $60.10
- EVENITY (Biological) $51.43
- SIMPONI ARIA (Biological) $40.41
- Cimzia (Drug) $33.37
- Arcalyst (Drug) $28.62
- OFEV (Drug) $26.60
- IDACIO (Biological) $25.44
- REMICADE (Biological) $25.13
- KEVZARA (Biological) $24.35
- ORENCIA (Biological) $22.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Physician Assistant Doctors in Salem
Shawn Hill, Mpas, MPAS
Physician Assistant — Payments: $16,101
Physician Assistant $16,101
Mrs. Olivia Darwin, Pa-C, PA-C
Physician Assistant — Payments: $9,122
Physician Assistant $9,122
Shannon Snyder, Pa-C, PA-C
Physician Assistant — Payments: $8,469
Physician Assistant $8,469
Eric Harmon, Pa, PA
Physician Assistant — Payments: $8,455
Physician Assistant $8,455
Robert Wollenzien
Physician Assistant — Payments: $7,551
Physician Assistant $7,551
Jordan Young, Pa-C, PA-C
Physician Assistant — Payments: $7,356
Physician Assistant $7,356